|
Objective: LPS (Lipopolysaccharide, LPS) stimulated human umbilical vein endothelial cells, endothelial cells in vitro inflammatory state, the concept of atorvastatin, LXR agonist T0901317 and their combination on the LPS-stimulated human umbilical vein endothelial cells cholesterol regulating receptor LXRα and its target genes ABCA1 SREBP-lc, inflammatory cytokines IL-6, adhesion molecules PEC AM-1 ICAM-1 mRNA expression, and to explore the underlying mechanism. Methods: Human umbilical vein endothelial cells with 10% fetal bovine serum, 1%, double anti-(streptomycin / penicillin) of Gibco1640 medium and cultured cell count were cultured according to the 6-well plates, the following experimental intervention . ① control group (adding 2μl in PBS) and lipopolysaccharide intervention group (with a final concentration of 100ng/ml LPS of intervention cells 24 hours); ② atorvastatin intervention group (with different concentrations of atorvastatin 0.1μmol / L, 1μmol / L 10μmol / L and DMSO) interference cells for 2 hours, then added 22 hours LPS common intervention; ③ LXR agonist T0901317 group (first with T0901317 1μmol / L or DMSO interfere cells for 2 hours, then added together lipopolysaccharide Intervention 22 hours); ④ T0901317 atorvastatin group (first with DMSO. atorvastatin, T0901317, and T0901317 atorvastatin and common interventions for 2 hours, then add 100ng/ml LPS common intervention 22 hours). After all of the above experiments, cells were harvested using Trizol extraction of total RNA, and then reverse, parallel real-time PCR for semi-quantitative determination. Comparing each group LXRα and its target genes, inflammatory cytokines and adhesion molecules expression. RESULTS: Compared with control group, LPS can inhibit human umbilical vein endothelial cells LXRα and its target gene ABCA1, SREBP-1 mRNA expression, and promote inflammatory cytokines IL-6 and adhesion molecules ICAM-1, PECAM-1 mRNA in expression; atorvastatin concentration-dependent manner can increase their corresponding cells LXRα target gene expression, inhibition of the corresponding expression of inflammatory cytokines and adhesion molecules, which can significantly increase T0901317 cells LXRα, ABCA1 and SREBP-1 expression , inhibition of IL-6, ICAM-1 and PECAM-1 expression; T0901317 and atorvastatin combination can significantly enhance the expression of these genes. Conclusion: 1, LPS can inhibit human umbilical vein endothelial cells LXRα and its target genes; 2, atorvastatin may be partially through LXRα signaling pathway inhibit endothelial cell inflammatory state; 3, LXR agonist T0901317 with improved endothelial cells functional role; 4, atorvastatin combined with LXR agonists on the inhibition of endothelial cell inflammatory response synergies.
|